We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+10.39%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.43B
AUM Growth
+$112M
(+4.8%)
Cap. Flow
+$19.8M
Cap. Flow
% of AUM
0.82%
Top 10 Holdings %
Top 10 Hldgs %
44.17%
Holding
71
New
12
Increased
26
Reduced
26
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$54.8M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$38.3M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$32M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$25.1M |
| 5 |
PTC Therapeutics
PTCT
|
+$23.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$50.2M |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$25.3M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$24.8M |
| 4 |
Merck
MRK
|
+$23.2M |
| 5 |
CELG
Celgene Corp
CELG
|
+$22.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amgen
AMGN
$198B
| $173M | 7.13% |
1,405,062
+142,429
| +11% | +$17.3M |
|
2
Biogen
BIIB
$30.4B
| $164M | 6.75% |
536,393
-8,182
| -2% | -$2.6M |
|
3
Gilead Sciences
GILD
$167B
| $146M | 6% |
2,057,416
+115,843
| +6% | +$9.09M |
|
|
4
Thermo Fisher Scientific
TMO
$198B
| $94.4M | 3.89% |
785,500
+268,900
| +52% | +$32M |
|
5
Regeneron Pharmaceuticals
REGN
$70.9B
| $92.3M | 3.8% |
307,400
+31,400
| +11% | +$9.67M |
|
6
Vertex Pharmaceuticals
VRTX
$123B
| $90.3M | 3.71% |
1,276,741
+44,583
| +4% | +$3.53M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
| $83.4M | 3.43% |
548,008
+51,700
| +10% | +$8.22M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $79M | 3.25% |
1,132,472
-280,400
| -20% | -$22.2M |
|
|
9
Teva Pharmaceuticals
TEVA
$37.3B
| $76.2M | 3.13% |
1,441,992
+828,343
| +135% | +$38.3M |
|
10
Incyte
INCY
$23.4B
| $75.1M | 3.09% |
1,403,160
+217,900
| +18% | +$13.5M |
|
11
Halozyme
HALO
$9.23B
| $68M | 2.8% |
5,355,488
+654,126
| +14% | +$9.71M |
|
12
Viatris
VTRS
$20.1B
| $67.9M | 2.79% |
1,390,697
+21,990
| +2% | +$1.07M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.5B
| $63.3M | 2.6% |
927,406
+213,600
| +30% | +$15.7M |
|
|
AGN
14
DELISTED
Allergan Inc
AGN
| $61.6M | 2.53% |
496,548
-64,785
| -12% | -$7.89M |
|
|
AGN
15
DELISTED
Allergan plc
AGN
| $60.5M | 2.49% |
293,950
-13,200
| -4% | -$2.61M |
|
|
KERX
16
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $60.3M | 2.48% |
3,537,590
+778,640
| +28% | +$11.7M |
|
|
SHPG
17
DELISTED
Shire pic
SHPG
| $58.1M | 2.39% |
391,197
-77,562
| -17% | -$12M |
|
18
Innoviva
INVA
$1.6B
| $57.3M | 2.36% |
2,297,200
-151,526
| -6% | -$4.44M |
|
19
Ironwood Pharmaceuticals
IRWD
$635M
| $57.2M | 2.35% |
5,542,765
-528,724
| -9% | -$5.94M |
|
|
IMGN
20
DELISTED
Immunogen Inc
IMGN
| $54.1M | 2.23% |
3,623,786
+110,504
| +3% | +$1.74M |
|
|
OMED
21
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $45.3M | 1.87% |
1,347,642
+127,636
| +10% | +$4.3M |
|
|
AEGR
22
DELISTED
Aegerion Pharmaceuticals
AEGR
| $43.1M | 1.77% |
+934,100
| New | +$54.8M |
|
|
NPSP
23
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $42.2M | 1.73% |
1,408,729
-366,190
| -21% | -$12.6M |
|
|
GEVA
24
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $38.6M | 1.59% |
465,145
-273,860
| -37% | -$25.3M |
|
25
Ionis Pharmaceuticals
IONS
$8.99B
| $38.1M | 1.57% |
882,101
-340,300
| -28% | -$16.5M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q1 2014 Portfolio in Review
As of Q1 2014, Sectoral Asset Management held 71 positions worth $2.43B, up 4.8% from $2.32B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sectoral Asset Management's Q1 2014 filing shows 12 new, 26 increased, 26 reduced and 7 closed positions. Its largest new stake was Aegerion Pharmaceuticals: 934,100 shares worth $43.1M. The largest sale was Perrigo, an estimated $50.2M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier.
- Sectoral Asset Management's largest Q1 2014 buy was Aegerion Pharmaceuticals: 934,100 shares worth $43.1M.
- Sectoral Asset Management added most to Teva Pharmaceuticals in Q1 2014, an estimated $38.3M increase.
- Sectoral Asset Management's biggest Q1 2014 reduction was SYNAGEVA BIOPHARMA CORP COM STK (DE), cutting an estimated $25.3M.
- Sectoral Asset Management fully exited Perrigo in Q1 2014, selling an estimated $50.2M.
- Sectoral Asset Management's ten largest holdings make up 44% of its $2.43B portfolio in Q1 2014.
- Sectoral Asset Management opened 12 new positions and closed 7 in Q1 2014.
- Sectoral Asset Management's portfolio value rose 4.8% quarter-over-quarter to $2.43B.
Based on Sectoral Asset Management's 13F filing for Q1 2014, filed 14 May 2014.